Larazotide vs hBD-1
Head-to-head comparison of Larazotide (Larazotide acetate (AT-1001)) and hBD-1 (Human beta-defensin 1) — benefits, dosing, side effects, research data, and where to buy.
Research Score
| Property | Larazotide | hBD-1 |
|---|---|---|
| Category | Gastrointestinal | Dental & Oral |
| Full Name | Larazotide acetate (AT-1001) | Human beta-defensin 1 |
| Molecular Weight | N/A | 4490 Da |
| Half-Life | short; designed for local gut action | minutes to hours |
| Amino Acids | 8 | 36 |
| Typical Dose | 0.5-4 mg TID (clinical studies) | 1-10 µg/mL in experimental studies |
| Route | Oral | Topical/Intraoral |
| Purity | ≥98% | ≥98% |
| Studies Count | 40 | 85 |
| Research Status | Clinical | Pre-clinical |
Larazotide Benefits
- ✓tight-junction-support
- ✓reduced-permeability
- ✓symptom-reduction
- ✓barrier-protection
hBD-1 Benefits
- ✓oral innate immunity
- ✓broad antimicrobial activity
- ✓biofilm suppression
- ✓periodontal support
Larazotide Dosing
0.5-4 mg orally before meals in clinical trials|typically three times daily|short-course or chronic study protocols
hBD-1 Dosing
topical peptide exposure|cell-culture or mucosal models|repeat low-dose application in research
Larazotide Side Effects
- ⚠headache
- ⚠nausea
- ⚠abdominal discomfort
hBD-1 Side Effects
- ⚠protease degradation
- ⚠local irritation at high dose
- ⚠limited stability in saliva
Research Overview
Larazotide
Clinical and translational studies suggest larazotide can reduce antigen passage across the epithelium and improve gut barrier function. It is one of the better-known peptides for intestinal permeability and barrier-focused gastrointestinal therapy.
hBD-1
hBD-1 has been studied as part of the oral mucosal defense system and is linked to host resistance against dental pathogens. Research spans periodontitis, candidiasis, and epithelial barrier biology.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.